AIM ImmunoTech Inc. (0A4Y)
LSE 
Summary
0A4Y Chart
Thruvision shares surge 46% to 0.91p on £3m Asian airport contract
Thruvision Group PLC (AIM:THRU, OTC:DIGTF) shares jumped 46% to 0.91p after the security screening group landed its largest contract in Asia to date. The AIM-listed company said its principal regional partner has won a deal to deploy Thruvision systems across several major airports in South-East Asia, generating more than £3 million of revenue.
Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating
Cavendish sees almost fivefold upside in Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) after regulators extended the Verbier licence, giving the partners more time to advance an integrated Greater Buchan Area development. The broker has repeated a Buy recommendation and 537p price target, representing 388% upside from the AIM-listed company's 110p share price.
Cavendish sees 18-fold upside at 88 Energy on Alaska prospect scale
Cavendish has reiterated its buy rating and 19.8p target price on 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), implying significant untapped upside from the current 1.02p share price. The AIM-listed oil and gas explorer's South Prudhoe acreage on Alaska's North Slope now holds 768.9 million barrels of gross prospective resources, of which 640.7 million barrels are net to the company.
AIM ImmunoTech Inc. (0A4Y) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AIM ImmunoTech Inc. ever had a stock split?
AIM ImmunoTech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Thomas K. Equels CEO | LSE Exchange | US00901B3033 ISIN |
| US Country | 19 Employees | - Last Dividend | 10 Feb 2026 Last Split | 12 Jul 1996 IPO Date |
Overview
AIM ImmunoTech Inc. is an immuno-pharma company primarily engaged in the research and development of therapeutic treatments for a wide variety of cancers, viral diseases, and immune-deficiency disorders within the United States. The company, which was originally founded in 1966 and known as Hemispherx Biopharma, Inc., underwent a name change to AIM ImmunoTech Inc. in August 2019, marking a new phase in its operation. With its headquarters in Ocala, Florida, AIM ImmunoTech Inc. has established several strategic agreements with entities such as Amarex Clinical Research LLC, University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente, Jubilant HollisterStier, Sterling Pharma Solutions, Erasmus University Medical Center Rotterdam, Azenova, LLC, and Alcami Corporation. These collaborations underscore the company’s commitment to advancing its pipeline of innovative treatments.
Products and Services
- Ampligen
- Alferon N Injection
As AIM ImmunoTech's leading product candidate, Ampligen represents a significant advancement in the treatment of Chronic Fatigue Syndrome (CFS) with its unique composition of macromolecular ribonucleic acid molecules. Beyond CFS, the company is expanding its potential applications to a broader spectrum of diseases, including pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers. Additionally, it is being developed for conditions such as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions, showcasing the versatility of this innovative therapeutic.
This injectable formulation of natural alpha interferon offered by AIM ImmunoTech is approved for the treatment of human papillomavirus (HPV) infections and genital warts, a common sexually transmitted disease. Alferon N Injection highlights the company's commitment to addressing a range of infectious diseases with effective treatment options.
